Literature DB >> 24422477

Synthesis and biological properties of Quilamines II, new iron chelators with antiproliferative activities.

Vincent Corcé1, Stéphanie Renaud, Isabelle Cannie, Karine Julienne, Sébastien G Gouin, Olivier Loréal, François Gaboriau, David Deniaud.   

Abstract

To selectively target tumor cells expressing an overactive Polyamine Transport System (PTS), we designed, synthesized, and evaluated the biological activity of a new generation of iron chelators, derived from the lead compound HQ1-44, which we named Quilamines II. The structures of four new antiproliferative agents were developed. They differ in the size of the linker (HQ0-44 and HQ2-44) or in the nature of the linker (HQCO-44 and HQCS-44) between a hydroxyquinoline moiety (HQ) and a homospermidine (44) chain, the best polyamine vector. The Quilamines II were obtained after 6 to 9 steps by Michael addition, peptide linkage, and reductive amination or by using the Willgerodt-Kindler reaction. The biological evaluation of these second-generation Quilamines showed that modifying the size of the linker increased the selectivity of these compounds for the PTS. In addition, measurement of the toxicity of Quilamines HQ0-44 and HQ2-44 highlighted their marked antiproliferative nature on several cancerous cell lines as well as a differential activity on nontransformed cells (fibroblasts). In contrast, Quilamines HQCO-44 and HQCS-44 presented low selectivity for the PTS, probably due to a loss of electrostatic interaction. We also demonstrated that the HCT116 cell line, originating from a human colon adenocarcinoma, was the most responsive to the various Quilamines. As deduced from the calcein and HVA assays, the higher iron chelating capacity of HQ1-44 could explain its higher antiproliferative efficiency.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24422477     DOI: 10.1021/bc4004734

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  4 in total

1.  Synthesis and antitumor mechanism of a new iron(iii) complex with 5,7-dichloro-2-methyl-8-quinolinol as ligands.

Authors:  Bi-Qun Zou; Qi-Pin Qin; Yu-Xia Bai; Qian-Qian Cao; Ye Zhang; Yan-Cheng Liu; Zhen-Feng Chen; Hong Liang
Journal:  Medchemcomm       Date:  2017-02-01       Impact factor: 3.597

2.  Synthesis, crystal structure, cytotoxicity and action mechanism of a Rh(iii) complex with 8-hydroxy-2-methylquinoline as a ligand.

Authors:  Yun-Liang Zhang; Qi-Pin Qin; Qian-Qian Cao; Hong-Hua Han; Zhu-Ling Liu; Yan-Cheng Liu; Hong Liang; Zhen-Feng Chen
Journal:  Medchemcomm       Date:  2016-10-25       Impact factor: 3.597

3.  Crystal structure of bis-{μ-(E)-2-[(2-oxido-phenyl-imino)-meth-yl]quinolin-8-olato-κ4O,N,N',O'}bis-[di-butyl-tin(IV)].

Authors:  Camacho-Camacho Carlos; Ortiz-Pastrana Naytzé; Garza-Ortiz Ariadna; Rojas-Oviedo Irma
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2017-01-01

4.  Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.

Authors:  Claire Legendre; Sylvie Avril; Catherine Guillet; Emmanuel Garcion
Journal:  BMC Cancer       Date:  2016-02-01       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.